Elutia Raises $54 Million to Fund Drug-Eluting Platform Launch

Elutia has secured $54 million in total capital. The company states this funding will support the commercial launch of its drug-eluting biomatrix platform and eliminate the need for additional equity offerings. The company, which targets the market for surgical site infections, presented a multi-year regulatory and commercial roadmap during the H.C. Wainwright investment conference.

"We combine a biological matrix with sustained local delivery of powerful antibiotics directly at the surgical site," said CEO Randy Mills.

Capital Structure and Financial Outlook

The $54 million capital infusion comes from several liquidity sources. According to a transcript of the presentation, this includes $20 million in cash, a $15 million credit facility, $8 million from the divestiture of its SimpliDerm product line, and $8 million held in escrow from the sale of EluPro.

As of September 14, 2026, Elutia Inc (ELUT) stock traded at $0.85, a 4.80% increase for the day. The company is managing its financial runway to support the development of its NXT-41 platform, which addresses high-cost complications in surgical procedures.

Addressing Surgical Site Infections

Elutia focuses on reducing post-operative infections, which remain a burden on the U.S. healthcare system. The company aims to replace traditional systemic antibiotic treatments with localized delivery systems.

"Surgical infection is the most costly healthcare-associated infection in the United States," said Mills. "There are 300,000 of them a year. Each one adds an average of 9.7 days to a hospital stay, and the annual cost to our healthcare system is a staggering $3.3 billion."

Regulatory and Launch Timeline

The company provided specific milestones for its pipeline and the path to market for its lead candidates:

• NXT-41: Clearance is expected in Q4 2024.
• NXT-41x: Regulatory clearance is anticipated in the first half of 2027.
• Commercial Launch: A soft launch is scheduled for the second half of 2027, followed by a full-scale commercial rollout in 2028.

By securing this capital, Elutia intends to bridge the gap between current regulatory filings and the commercialization of its technology, reducing the risk of dilution for current shareholders during the development phase.